Trials / Active Not Recruiting
Active Not RecruitingNCT03899857
Pembrolizumab for Newly Diagnosed Glioblastoma
Pembrolizumab for Newly Diagnosed Glioblastoma: a Prospective, Open-label, Single-arm, Multicenter Phase II Study
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- University of Zurich · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study explores the addition of pembrolizumab to temozolomide-based radiotherapy in patients with newly diagnosed glioblastoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Pembrolizumab will be added to standard of care |
Timeline
- Start date
- 2020-10-21
- Primary completion
- 2026-04-30
- Completion
- 2026-12-01
- First posted
- 2019-04-02
- Last updated
- 2024-05-08
Locations
3 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT03899857. Inclusion in this directory is not an endorsement.